Northwest Biotherapeutics

Northwest Biotherapeutics, Inc. is a development stage biotechnology company based in Bethesda, Maryland. The company employs 15 people. Northwest Biotherapeutics focuses on developing immunotherapy products that enhance the body's immune system to treat cancer. Their unique approach utilizes dendritic cells, a type of white blood cell, to stimulate a targeted immune response against cancer cells. The company's platform technology, DCVax®, involves extracting a patient's dendritic cells, loading them with tumor-specific antigens, and re-injecting them to trigger a personalized immune response. This personalized immunotherapy approach aims to provide superior clinical benefits and a better quality of life for patients compared to conventional cancer treatments. The company's lead product candidate, DCVax®-Brain, targets Glioblastoma Multiforme (GBM), the most lethal form of brain cancer. DCVax®-Brain has completed a Phase II clinical trial and the company plans to file a Biologic License Application (BLA) with the FDA following the trial's completion. DCVax®-Prostate, targeting advanced prostate cancer, has also been granted FDA clearance to begin a Phase III clinical trial. For more information about Northwest Biotherapeutics and its innovative cancer therapies, please visit their website at nwbio.com.